Triptans — supply limits and quantity overrides
Defines quantity/supply limits and criteria for approving requests that exceed standard copayment/coinsurance limits for triptan agents for migraine for UnitedHealthcare (Oxford). Affects providers requesting higher quantities for members.
Effective date set for Oxford plan: 1/1/2026.
Added Tosymra to the policy and updated supply limits.
Removed multiple brands (almotriptan, Frova, Relpax tablets, Zomig tablets, etc.) as standard supply limits were increased or they were off market.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.